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A patient is presented who developed hepatic osteo-
dystrophy after orthotopic liver transplantation in asso-
ciation with persistently low serum 25-hydroxyvitamin D 
levels. After successful liver transplantation there was a 
delay in the return to normal of the serum 25-hydroxy-
vitamin D levels until oral supplementation with vitamin 
D was instituted. This case emphasizes the need for 
effective treatment of hepatic osteodystrophy with vi-
tamin D especially in patients considered for transplan-
tation. 
INTRODUCTION 
Recent studies have shown that intramuscular 1-25-
dihydroxyvitamin D (1), oral la-hydroxyvitamin D3 (2), 
oral 25-hydroxyvitamin D3 (3), and frequent large intra-
muscular doses of vitamin D2 (4, 5) may heal the bone 
lesions associated with primary biliary cirrhosis. The 
patient presented here had progressive primary biliary 
cirrhosis and was treated with large daily doses of oral 
vitamin D before the development of bone symptoms_ 
After hepatic transplantation for severe liver disease 
vitamin D was stopped because vitamin D metabolism 
was presumed to be norma1. Three months after trans-
plantation, the patient developed severe bone pain and 
multiple compression fractures of the spine despite ap-
parent normal liver function. Her symptoms improved 
dramatically after 6 wk of oral vitamin D therapy_ Levels 
of25-hydroxyvitaminD were measured on frozen serum 
samples obtained throughout the 18 months before and 
3 yr after transplantation. 
CASE REPORT 
The patient ftrst presented to The Mary Imogene 
Bassett Hospital in July 1976 at age 46 with painless 
jaundice. She had had a cholecystectomy performed 
elsewhere in 1970 for gallstones. 
Initial physical examination revealed jaundice and a 
slightly enlarged liver. Serum enzymes showed an alka-
line phosphatase of 1225 U /L (normal 30-1(0), bilirubin 
of 133 mol/L (7.7 mgllOO ml), and a serum glutamate 
oxaloacetate transaminase of 167 U/L (normal 0-40). 
Antimitochondrial antibody was positive at a 1:160 di-' 
102 
lution. A normal pancreatic duct and a normal biliary 
tree were demonstrated by endoscopic retrograde cho-
langiopancreatography. Liver biopsy interpretation was 
consistent with primary biliary cirrhosis. 
By early 1977, therapy ~cluded cholestyramine, me-
dium-chain triglyceride dietary supplementation, and 
1.25 mg of oral vitamin D2 each day. In June 1977, the 
patient developed melena but upper gastrointestinal se-
ries, barium enema, colonoscopy, and gastroscopy 
showed only duodenitis. She was treated initially with 2 
oz of Amphogel daily and subsequently with Mylanta, 
2-4 oz daily. This was continued after transplantation. 
In December 1977, her itching became unbearable and 
methyltestosterone was administered with dramatic im-
provement in this symptom. In March 1978, she devel-
oped mild pain in the bones of the lower legs; the dose 
of oral vitamin D2 was increased to 1.25 mg daily alter-
nated with 2.5 mg, and a single intramuscular dose of 
vitamin D2 (1.25 mg) was administered. At this time, her 
serum bilirubin had reached 879 mol/L (51 mg/100 ml), 
serum cholesterol was decreasing, and xanthomatous 
skin deposits were regressing. Because of these ominous 
signs, it was decided to attempt liver transplantation. 
Further intramuscular vitamin D2 was not given. No 
corticosteroids were given before transplantation. 
In June 1978, liver transplantation was performed at 
the University of Colorado. At discharge, her immuno-
suppression consisted of prednisone 30 mg in divided 
doses and azathioprine 100 mg. In September 1978, she 
developed back pain attributed to compression fractures 
of her spine. At the same time, her serum alkaline 
phosphatase and glutamate oxaloacetate transaminase 
became markedly elevated (Fig. 1). It was presumed that 
she was undergoing a rejection reaction, and large doses 
of corticosteroids were given. At the same time, her 
serum ftrst became positive for hepatitis B surface anti-
gen. Her serum glutamate oxaloacetate transaminase 
level decreased to the levels seen before the "rejection" 
but the serum alkaline phosphatase continued to be 
markedly elevated. Heat fractionation of the serum al-
kaline phosphatase suggested a major origin of the en-
zyme from bone. In November, alkaline phosphatase 
was 402 U/L and heated alkaline phosphatase was 154 
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FIG. J. Laboratory studies 18 months before transplantation and 3 yr after transplantation. (Conversion SI to traditional units: serum bilirubin 
1 mol/L 0.058 mgllOO ml, 25-hydroxyvitamin D 1 nmol/L 0.4 nglml). Normal ranges: 25-hydroxyvitamin D 25-138 nmol/L, bilirubin 0-17 moll 
L, alkaline phosphatase 30-100 units/L, serum glutamate oxaloacetate transaminase (GOT) 0--40 units/L. Liver transplantation took place in June 
1978. 
U/L. In December, alkaline phosphatase was 393 U/L 
and heated alkaline phosphatase was 193 U /L. Oral 
vitamin D2 1.25 mg twice a week and calcium 1.0 g/day 
were begun. After 6 wk, the serum alkaline phosphatase 
level decreased and her generalized bone pain, which 
had become quite severe involving primarily the ribs and 
sternum, subsided. Oral vitamin D2 at 1.25 mg/wk has 
been continued to date (September 1982) with the patient 
free of bone pain since February 1979. She continues to 
do well with maintenance immunosuppression of 22.5 . 
mg of prednisone in one dose and 100 mg of azathioprine 
as of September 1982. Figures 2 to 5 illustrate bony 
demineralization, compression fractures of the spine, and 
. fracture of the sternum consistent with metabolic bone 
disease. They also show the development of curvature of 
the sternum consistent with osteomalacia. 
Laboratory studies illustrating the clinical course are 
shown in Figure 1. Specific 25-hydroxyvitamin 0 levels 
are shown in Table I. During the patient's entire period 
of observation from July 1976, her serum calcium and 
phosphate levels have remained in a normal range. The 
range for calcium was 8.9-9.7 mg/dl and phosphate 
2.4-3.9 mg/dl. Only one phosphate determination was 
2.4 mg/dl. Her antimitochondrial antibody was negative 
5 months after. transplantation but was again positive in 
August 1980 (1:640 titer). 
Hepatic chemistries were measured by standard au-
toanalyzer techniques. Determination of 25-hydroxyvi-
tamin D levels was accomplished on serum samples 
preserved at -20°C using a commercially available com-
petitive protein binding assay based on Haddad's meth-
ods (6). 
DISCUSSION 
Hepatic osteodystrophy is a general term that describes 
the metabolic bone disease found in certain cases of 
chronic liver disease. This disorder is most clearly man-
ifested in patients with primary biliary cirrhosis. Histo-
logically, the fmdings are those of both osteomalacia and 
osteoporosis. The osteomalacia is not usually associated 
with either hypocalcemia or with secondary hyperpara-
thyroidism (1, 7). The pathogenesis of this metabolic 
bone disease is not entirely clear. Abnormalities of vi-
tamin D metabolism have been implicated (I, 5), since 
25-hydroxyvitamin D, the major circulating form of 
vitamin D, is synthesized mainly in the liver of humans. 
Serum levels of 25-hydroxyvitamin D have been found 
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FIG. 2. Lateral chest x-ray June 1978 prior to transplantation show-
ing a structurally nonnal sternum and demineralization of the spine. 
to be reduced in some patients with severe primary 
biliary cirrhosis with the bone lesions of hepatic osteo-
dystrophy (5) and normal in some others (1). Possible 
reasons for decreased 25-hydroxyvitamin D levels are 
decreased hepatic 25-hydroxylation of vitamin D, mal-
absorption of vitamin D, and increased urinary losses of 
vitamin D or of its metabolites (8,9). 
Studies have demonstrated that the osteomalacia as-
sociated with hepatic osteodystrophy does respond to 
vitamin D therapy in some instances (1-5). Skinner el al. 
(5) found that serum 25-hydroxyvitamin D concentra-
tions could be raised if large doses of vitamin D were 
provided with monthly intramuscular injections. Most 
studies have suggested that patients with primary biliary 
cirrhosis are capable of making at least some 25-hydroxy-
vitamin D from very large parenteral doses (10). 
Low serum levels of 25-hydroxyvitamin D were pres-
ent in this patient before hepatic transplantation. This 
occurred despite the oral intake of 1.25 mg of vitamin 
D2 daily for 18 months. With progression of the liver 
disease, she began to develop bone pain 2 months before 
transplantation. At this time her serum vitamin D level 
was 22.5 nmol/L (normal 25-138). A single parenteral 
dose of vitamin D2 was given shortly before orthotopic 
liver transplantation (II, 12). 
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No supple~ental vitamin D was administered in the 
immediate posttransplantation period. Three months 
after transplantation, at the time of development of 
severe bone pain and vertebral collapse, serum 25..:hy-
droxyvitamin D levels continued to be low (Fig. I and 
Table I). 
When bone pain developed 3 months after transplan-
tation, 1.25 mg of vitamin D2 given orally twice weekly 
led to relief of bone pain and lowered serum alkaline 
phosphatase levels. Six weeks after concluding a course 
of vitamin D2 1.25 mg, twice weekly, the 25-hydroxyvi-
tamin D level remained low even though clinical im-
provement was apparent (Table I). 
This patient's bone symptoms may have been in part 
due to osteoporosis, but the severe clinical manifestations 
of rib and sternal pain, the apparent response to vitamin 
D, as well as the deformity which developed in the 
sternum, suggest that the osteomalacia of hepatic osteo-
dystrophy played a major role in this patient's bone 
disease. Bone biopsies are not available to confirm this. 
The bone disease in this woman was undoubtedly 
multifactorial. She took antacids before and after the 
transplantation. Antacids may cause phosphate malab-
sorption which can then lead to osteomalacia (13). How-
ever, her serum phosphate levels were normal repeatedly, 
FIG. 3. Lateral chest x-ray December 1978 showing compression 
fractures of the spine. 
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FIG. 4. Lateral chest x-ray March 1979 showing healed sternal 
fracture and increased curvature of the sternum. 
with one exception of a value of 2.4 mgldl, so that 
osteomalacia solely due to antacid ingestion seems un-
likely, but it may have been a contributing factor. 
The exact role of vitamin D metabolites in the min-
eralization of bone is not known (14). Normal levels of 
1.,25 dihydroxyvitamin D have been reported in patients 
with osteomalacia (15). Since 25-hydroxyvitamin D is 
the major circulating form of vitamin D, a vitamin D 
depleted state was present before transplantation, as 
documented by low 25-hydroxyvitamin D levels done on 
frozen serum samples retrospectively (Table I). This may 
have been due to malabsorption and possible decreased 
25-hydroxylation. Use of Questran may also have con-
tributed to the loss of vitamin D by binding vitamin D 
and interrupting the enterohepatic circulation of vitamin 
D. Postoperatively the patient had a prolonged hospital-
ization with absent sun exposure, and vitamin D stores 
were not replaced pharmacologically. Corticosteroid 
therapy may also alter vitamin D metabolism and lead 
to depressed 25-0H vitamin D levels (16) by metabolism 
of 1-25 dihydroxyvitamin D (17, 18) to a more polar, 
biologically inactive metabolite. These effects on vitamin 
D metabolism may then lead to decreased intestinal 
Ca ++ absorption (17, 18). 
This patient's course suggests that patients who might 
not ordinarily survive their liver disease to develop he-
patic osteodystrophy, if treated with liver transplantation 
may develop severe bone complications. This complica-
tion might be prevented if careful attention is paid to 
vitamin D treatment. In those patients on corticosteroids 
vitamin D therapy may also improve or delay bone 
changes seen with glucocorticoid-induced osteopenia 
(19). 
FIG. 5. Lateral chest x-ray January 1981 showing increased min-
eralization of the spine (healed sternal fracture and sternal curvature 
similar to March 1979). 
TABLE I 
25-Hydroxyvilamin D Levels 
25-Hydroxyvitamin D 
(n = 25- 138 nmol/L) 
September 1977 
January 1978 
March 1978 
September 1978 
January 1979 
March 1980 
August 1980 
February 1981 
July 1981 
17.5 
7.5 
22.5 
25 
30 
70 
55 
70 
156 
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